XML 113 R40.htm IDEA: XBRL DOCUMENT v3.22.4
Segmentation of key figures (Tables)
 12 Months Ended
Dec. 31, 2022
Statement [line items]  
Segmentation - Consolidated income statements
Segmentation – consolidated income statements
Innovative Medicines
Sandoz
Corporate (including eliminations)1
Group
(USD millions)
2022
2021
2022
2021
2022
2021
2022
2021
Net sales to third parties
41 296
41 995
9 249
9 631
50 545
51 626
Sales to other segments
825
795
205
180
-1 030
-975
Net sales
42 121
42 790
9 454
9 811
-1 030
-975
50 545
51 626
Other revenues
1 249
1 179
28
61
6
11
1 283
1 251
Cost of goods sold
-11 569
-11 751
-4 978
-5 147
1 061
1 031
-15 486
-15 867
Gross profit
31 801
32 218
4 504
4 725
37
67
36 342
37 010
Selling, general and administration
-11 679
-12 306
-2 062
-2 062
-512
-518
-14 253
-14 886
Research and development
-9 172
-8 641
-824
-899
-9 996
-9 540
Other income
531
1 149
103
233
171
470
805
1 852
Other expense
-2 695
-1 732
-273
-397
-733
-618
-3 701
-2 747
Operating income
8 786
10 688
1 448
1 600
-1 037
-599
9 197
11 689
(Loss)/income from associated companies
-2
5
2
2
-9
15 332
-9
15 339
Interest expense
-837
-811
Other financial income and expense
20
-80
Income before taxes
8 371
26 137
Income taxes
-1 416
-2 119
Net income
6 955
24 018
Attributable to:
   Shareholders of Novartis AG
6 955
24 021
   Non-controlling interests
0
-3
 
Included in net income are:
   Interest income
379
71
   Depreciation of property, plant and equipment
-837
-859
-204
-210
-122
-139
-1 163
-1 208
   Depreciation of right-of-use assets
-252
-265
-33
-39
-15
-14
-300
-318
   Amortization of intangible assets
-3 728
-3 638
-222
-238
-32
-27
-3 982
-3 903
   Impairment charges on property, plant and equipment, net
-407
-271
-9
-1
-407
-281
   Impairment of right-of-use assets
-3
-3
   Impairment charges on intangible assets, net
-1 299
-367
-25
-28
-2
-8
-1 326
-403
   Impairment charges and fair value changes on financial assets, net
-134
43
-126
-5
-260
38
   Additions to restructuring provisions
-1 069
-240
-40
-62
-259
-26
-1 368
-328
   Equity-based compensation of Novartis equity plans
-706
-721
-62
-65
-280
-193
-1 048
-979
    
 1  Eliminations mainly relate to the elimination of sales to other segments and the corresponding cost of goods sold.
    
Innovative Medicines
Sandoz
Corporate (including eliminations)1
Group
(USD millions)
2021
2020
2021
2020
2021
2020
2021
2020
Net sales to third parties
41 995
39 013
9 631
9 646
51 626
48 659
Sales to other segments
795
792
180
189
-975
-981
Net sales
42 790
39 805
9 811
9 835
-975
-981
51 626
48 659
Other revenues
1 179
1 018
61
53
11
168
1 251
1 239
Cost of goods sold
-11 751
-10 927
-5 147
-5 252
1 031
1 058
-15 867
-15 121
Gross profit
32 218
29 896
4 725
4 636
67
245
37 010
34 777
Selling, general and administration
-12 306
-11 657
-2 062
-2 076
-518
-464
-14 886
-14 197
Research and development
-8 641
-8 118
-899
-862
-9 540
-8 980
Other income
1 149
922
233
176
470
644
1 852
1 742
Other expense
-1 732
-1 871
-397
-831
-618
-488
-2 747
-3 190
Operating income
10 688
9 172
1 600
1 043
-599
-63
11 689
10 152
Income from associated companies
5
1
2
2
15 332
670
15 339
673
Interest expense
-811
-869
Other financial income and expense
-80
-78
Income before taxes
26 137
9 878
Income taxes
-2 119
-1 807
Net income
24 018
8 071
Attributable to:
   Shareholders of Novartis AG
24 021
8 072
   Non-controlling interests
-3
-1
 
Included in net income are:
   Interest income
71
91
   Depreciation of property, plant and equipment
-859
-912
-210
-282
-139
-124
-1 208
-1 318
   Depreciation of right-of-use assets
-265
-273
-39
-41
-14
-16
-318
-330
   Amortization of intangible assets
-3 638
-3 080
-238
-370
-27
-12
-3 903
-3 462
   Impairment charges on property, plant and equipment, net
-271
-324
-9
-116
-1
-281
-440
   Impairment charges on intangible assets, net
-367
-768
-28
-141
-8
-5
-403
-914
   Impairment charges and fair value changes on financial assets, net
43
153
-5
182
38
335
   Additions to restructuring provisions
-240
-217
-62
-98
-26
-39
-328
-354
   Equity-based compensation of Novartis equity plans
-721
-714
-65
-64
-193
-180
-979
-958
 1  Eliminations mainly relate to the elimination of sales to other segments and the corresponding cost of goods sold.
    
Segmentation - Consolidated balance sheets
Segmentation – consolidated balance sheets
Innovative Medicines
Sandoz
Corporate (including eliminations)1
Group
(USD millions)
2022
2021
2022
2021
2022
2021
2022
2021
Total assets
75 510
79 220
16 078
16 192
25 865
36 383
117 453
131 795
Total liabilities
-16 966
-15 929
-3 710
-3 632
-37 354
-44 412
-58 030
-63 973
Total equity
59 423
67 822
Net debt 2
7 245
868
7 245
868
Net operating assets
58 544
63 291
12 368
12 560
-4 244
-7 161
66 668
68 690
 
Included in assets and liabilities are:
   Total property, plant and equipment
8 488
9 168
1 861
1 901
415
476
10 764
11 545
   Additions to property, plant and equipment  3
842
991
292
349
85
90
1 219
1 430
   Total right-of-use assets
1 233
1 349
90
104
108
108
1 431
1 561
   Additions to right-of-use assets 3
196
222
31
26
20
73
247
321
   Total goodwill and intangible assets
51 357
53 919
9 230
9 603
358
255
60 945
63 777
   Additions to goodwill and intangible assets  3
1 791
1 491
163
102
139
143
2 093
1 736
   Total investment in associated companies
107
170
9
7
27
28
143
205
   Additions to investment in associated companies
25
24
13
19
38
43
   Cash and cash equivalents, marketable securities, commodities, time deposits and derivative financial instruments
18 930
28 329
18 930
28 329
   Financial debts and derivative financial instruments
26 175
29 197
26 175
29 197
   Current income tax liabilities and deferred tax liabilities
5 219
5 485
5 219
5 485
 1  Eliminations mainly relate to the elimination of intercompany receivables and payables to other segments and inventories
 2  Note 29 provides additional disclosures related to net debt
 3  Excluding the impact of business acquisitions
Net sales and total of selected non-current assets, by countries and regions
Net sales to third parties1
Total of selected non-current assets2
(USD millions)
2022
%
2021
%
2020
%
2022
%
2021
%
Country
Switzerland
970
2
873
2
800
2
23 708
32
25 770
33
United States
17 653
35
16 818
33
16 484
34
35 353
48
37 054
48
France
2 257
4
2 522
5
2 442
5
3 188
4
3 615
5
Germany
4 278
8
4 870
9
4 518
9
2 229
3
2 378
3
China
3 128
6
3 052
6
2 573
5
599
1
703
1
Japan
2 205
4
2 683
5
2 804
6
165
217
Other
20 054
41
20 808
40
19 038
39
8 241
12
7 351
10
Group
50 545
100
51 626
100
48 659
100
73 483
100
77 088
100
 
Region
Europe
18 467
37
20 197
39
18 715
38
35 896
49
37 525
49
Americas
21 536
42
20 463
40
19 725
41
35 806
49
37 522
49
Asia/Africa/Australasia
10 542
21
10 966
21
10 219
21
1 781
2
2 041
2
Group
50 545
100
51 626
100
48 659
100
73 483
100
77 088
100
    
 1  Net sales to third parties by location of customer
 2  Total of property, plant and equipment; right-of-use assets; goodwill; intangible assets; investment in associated companies and other non-current assets excluding post-employment benefit assets
Net sales by region
Segmentation – net sales to third parties
Net sales to third parties by region1


2022
USD m


2021
USD m
Change
(2021
to 2022)
USD %


2020
USD m
Change
(2020
to 2021)
USD %
Innovative Medicines
Europe
13 554
14 919
-9
13 484
11
US
15 899
14 999
6
14 342
5
Asia/Africa/Australasia
8 929
9 304
-4
8 718
7
Canada and Latin America
2 914
2 773
5
2 469
12
Total
41 296
41 995
-2
39 013
8
   Of which in Established Markets
30 548
31 459
-3
29 643
6
   Of which in Emerging Growth Markets
10 748
10 536
2
9 370
12
 
Sandoz
Europe
4 913
5 278
-7
5 231
1
US
1 754
1 819
-4
2 142
-15
Asia/Africa/Australasia
1 613
1 662
-3
1 501
11
Canada and Latin America
969
872
11
772
13
Total
9 249
9 631
-4
9 646
0
   Of which in Established Markets
6 460
6 855
-6
7 089
-3
   Of which in Emerging Growth Markets
2 789
2 776
0
2 557
9
 
Group
Europe
18 467
20 197
-9
18 715
8
US
17 653
16 818
5
16 484
2
Asia/Africa/Australasia
10 542
10 966
-4
10 219
7
Canada and Latin America
3 883
3 645
7
3 241
12
Total
50 545
51 626
-2
48 659
6
   Of which in Established Markets
37 008
38 314
-3
36 732
4
   Of which in Emerging Growth Markets
13 537
13 312
2
11 927
12
 1  Net sales to third parties by location of customer. Emerging Growth Markets comprise all markets other than the Established Markets of the US, Canada, Western Europe, Japan, Australia and New Zealand.
    
Other revenue
Segmentation – other revenue
Innovative Medicines
Sandoz
Corporate (including eliminations)
Group
(USD millions)
2022
2021
2020
2022
2021
2020
2022
2021
2020
2022
2021
2020
Profit-sharing income
921
873
835
921
873
835
Royalty income
28
74
107
18
24
25
6
11
168
52
109
300
Milestone income
145
127
39
3
28
11
148
155
50
Other 1
155
105
37
7
9
17
162
114
54
Total other revenues
1 249
1 179
1 018
28
61
53
6
11
168
1 283
1 251
1 239
 1  Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales to third parties.
Innovative Medicines  
Statement [line items]  
Net sales
Innovative Medicines Division net sales to third parties by core therapeutic area; other promoted brands; and established brands


2022
USD m


2021
USD m1
Change
(2021 to
2022)
USD %


2020
USD m1
Change
(2020 to
2021)
USD %
Cardiovascular
Entresto
4 644
3 548
31
2 497
42
Leqvio
112
12
nm
nm
Total Cardiovascular
4 756
3 560
34
2 497
43
 
Immunology
Cosentyx
4 788
4 718
1
3 995
18
Xolair 2
1 365
1 428
-4
1 251
14
Ilaris
1 133
1 059
7
873
21
Other
1
nm
nm
Total Immunology
7 287
7 205
1
6 119
18
 
Neuroscience
Gilenya
2 013
2 787
-28
3 003
-7
Zolgensma
1 370
1 351
1
920
47
Kesimpta
1 092
372
194
15
nm
Mayzent
357
281
27
170
65
Aimovig
218
215
1
164
31
Other
1
1
0
nm
Total Neuroscience
5 051
5 007
1
4 272
17
Solid Tumors
Tafinlar + Mekinist
1 770
1 693
5
1 542
10
Kisqali
1 231
937
31
687
36
Votrient
474
577
-18
635
-9
Lutathera
471
475
-1
445
7
Piqray
373
329
13
320
3
Pluvicto
271
nm
2
nm
Tabrecta
133
90
48
35
157
Total Solid Tumors
4 723
4 101
15
3 666
12
 
Hematology
Promacta/Revolade
2 088
2 016
4
1 738
16
Tasigna
1 923
2 060
-7
1 958
5
Jakavi
1 561
1 595
-2
1 339
19
Kymriah
536
587
-9
474
24
Adakveo
194
164
18
105
56
Scemblix
149
7
nm
nm
Other
1
1
0
3
-67
Total Hematology
6 452
6 430
0
5 617
14


2022
USD m


2021
USD m1
Change
(2021 to
2022)
USD %


2020
USD m1
Change
(2020 to
2021)
USD %
Other Promoted Brands
Lucentis
1 874
2 160
-13
1 933
12
Xiidra
487
468
4
376
24
Ultibro Group
479
584
-18
623
-6
Beovu
203
186
9
190
-2
Other respiratory
84
53
58
26
104
Total Other Promoted Brands
3 127
3 451
-9
3 148
10
 
Total Promoted Brands
31 396
29 754
6
25 319
18
 
Established Brands
Sandostatin
1 238
1 413
-12
1 439
-2
Galvus Group
859
1 092
-21
1 199
-9
Gleevec/Glivec
745
1 024
-27
1 188
-14
Exforge Group
743
901
-18
980
-8
Diovan Group
652
773
-16
1 003
-23
Afinitor/Votubia
512
938
-45
1 083
-13
Voltaren/Cataflam
334
373
-10
360
4
Zortress/Certican
329
431
-24
452
-5
Exjade/Jadenu
323
563
-43
653
-14
Neoral/Sandimmun(e)
310
368
-16
393
-6
Contract manufacturing
214
108
98
nm
Other
3 641
4 257
-14
4 944
-14
Total Established Brands
9 900
12 241
-19
13 694
-11
 
Total division net sales to third parties
41 296
41 995
-2
39 013
8
 1  Reclassified to reflect the new Innovative Medicines divisional structures announced on April 4, 2022
 2  Net sales to third parties reflect Xolair sales for all indications.
    
Net sales of Top 20 products
Net sales to third parties of the top 20 Innovative Medicines Division brands in 2022

Brands
Brand classification by
therapeutic area, other
promoted brands or
established brands



Key indications


US
USD m

Rest of
world
USD m


Total
USD m
Cosentyx
Immunology
Psoriasis (PsO), ankylosing spondylitis (AS), psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSPA)
2 770
2 018
4 788
Entresto
Cardiovascular
Chronic heart failure, hypertension
2 354
2 290
4 644
Promacta/Revolade
Hematology
Immune thrombocytopenia (ITP), severe aplastic anemia (SAA)
1 083
1 005
2 088
Gilenya
Neuroscience
Relapsing multiple sclerosis (RMS)
1 153
860
2 013
Tasigna
Hematology
Chronic myeloid leukemia (CML)
877
1 046
1 923
Lucentis
Other Promoted Brands
Age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO)
1 874
1 874
Tafinlar + Mekinist
Solid Tumors
BRAF V600+ metastatic adjuvant melanoma, advanced non-small cell lung cancer (NSCLC), tumor agnostic with BRAF mutation indication
678
1 092
1 770
Jakavi
Hematology
Myelofibrosis (MF), polycytomia vera (PV), graft-versus-host disease (GvHD)
1 561
1 561
Zolgensma
Neuroscience
Spinal muscular atrophy (SMA)
434
936
1 370
Xolair 1
Immunology
Severe allergic asthma (SAA), chronic spontaneous urticaria (CSU), nasal polyps
1 365
1 365
Sandostatin
Established Brands
Carcinoid tumors, acromegaly
800
438
1 238
Kisqali
Solid Tumors
HR+/HER2- metastatic breast cancer
472
759
1 231
Ilaris
Immunology
Auto-inflammatory (CAPS, TRAPS, HIDS/MKD, FMF, SJIA, AOSD, gout)
570
563
1 133
Kesimpta
Neuroscience
Relapsing-remitting multiple sclerosis (RRMS)
921
171
1 092
Galvus Group
Established Brands
Type 2 diabetes
859
859
Gleevec/Glivec
Established Brands
Chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GIST)
205
540
745
Exforge Group
Established Brands
Hypertension
14
729
743
Diovan Group
Established Brands
Hypertension
55
597
652
Kymriah
Hematology
r/r pediatric and young adults acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL)
196
340
536
Afinitor/Votubia
Established Brands
Breast cancer/ tuberous sclerosis complex (TSC)
171
341
512
Top 20 brands total
12 753
19 384
32 137
Rest of portfolio
3 146
6 013
9 159
Total division net sales to third parties
15 899
25 397
41 296
 1  Net sales to third parties reflect Xolair sales for all indications.
Net sales to third parties of the top 20 Innovative Medicines Division brands in 2021

Brands
Brand classification by
therapeutic area, other
promoted brands or
established brands1



Key indications


US
USD m

Rest of
world
USD m


Total
USD m
Cosentyx
Immunology
Psoriasis (PsO), ankylosing spondylitis (AS), psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSPA)
2 883
1 835
4 718
Entresto
Cardiovascular
Chronic heart failure
1 712
1 836
3 548
Gilenya
Neuroscience
Relapsing multiple sclerosis (RMS)
1 427
1 360
2 787
Lucentis
Other Promoted Brands
Age-related macular degeneration (AMD)
2 160
2 160
Tasigna
Hematology
Chronic myeloid leukemia (CML)
882
1 178
2 060
Promacta/Revolade
Hematology
Immune thrombocytopenia (ITP), severe aplastic anemia (SAA)
947
1 069
2 016
Tafinlar + Mekinist
Solid Tumors
BRAF V600+ metastatic adjuvant melanoma, advanced non-small cell lung cancer (NSCLC)
606
1 087
1 693
Jakavi
Hematology
Myelofibrosis (MF), polycythemia vera (PV)
1 595
1 595
Xolair 2
Immunology
Severe allergic asthma (SAA), chronic spontaneous urticaria (CSU), nasal polyps
1 428
1 428
Sandostatin
Established Brands
Carcinoid tumors, acromegaly
843
570
1 413
Zolgensma
Neuroscience
Spinal muscular atrophy (SMA)
469
882
1 351
Galvus Group
Established Brands
Type 2 diabetes
1 092
1 092
Ilaris
Immunology
Auto-inflammatory (CAPS, TRAPS, HIDS/MKD, FMF, SJIA, AOSD, gout)
501
558
1 059
Gleevec/Glivec
Established Brands
Chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GIST)
263
761
1 024
Afinitor/Votubia
Established Brands
Breast cancer/ tuberous sclerosis complex (TSC)
521
417
938
Kisqali
Solid Tumors
HR+/HER2- metastatic breast cancer
339
598
937
Exforge Group
Established Brands
Hypertension
14
887
901
Diovan Group
Established Brands
Hypertension
51
722
773
Kymriah
Hematology
r/r pediatric and young adults acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL)
230
357
587
Ultibro Group
Other Promoted Brands
Cronic obstructive pulmonary disease (COPD)
584
584
Top 20 products total
11 688
20 976
32 664
Rest of portfolio
3 311
6 020
9 331
Total division net sales to third parties
14 999
26 996
41 995
 1  Brand classifications have been changed to reflect the new Innovative Medicines divisional structures announced on April 4, 2022.
 2  Net sales to third parties reflect Xolair sales for all indications.
Net sales to third parties of the top 20 Innovative Medicines Division brands in 2020

Brands
Brand classification by
therapeutic area, other
promoted brands or
established brands1



Key indications


US
USD m

Rest of
world
USD m


Total
USD m
Cosentyx
Immunology
Psoriasis (PsO), ankylosing spondylitis (AS), psoriatic arthritis (PsA)
2 516
1 479
3 995
Gilenya
Neuroscience
Relapsing multiple sclerosis (RMS)
1 562
1 441
3 003
Entresto
Cardiovascular
Chronic heart failure
1 277
1 220
2 497
Tasigna
Hematology
Chronic myeloid leukemia (CML)
859
1 099
1 958
Lucentis
Other Promoted Brands
Age-related macular degeneration (AMD)
1 933
1 933
Promacta/Revolade
Hematology
Immune thrombocytopenia (ITP), severe aplastic anemia (SAA)
833
905
1 738
Tafinlar + Mekinist
Solid Tumors
BRAF V600+ metastatic adjuvant melanoma, advanced non-small cell lung cancer (NSCLC)
569
973
1 542
Sandostatin
Established Brands
Carcinoid tumors, acromegaly
837
602
1 439
Jakavi
Hematology
Myelofibrosis (MF), polycythemia vera (PV)
1 339
1 339
Xolair 2
Immunology
Severe allergic asthma (SAA), chronic spontaneous urticaria (CSU)
1 251
1 251
Galvus Group
Established Brands
Type 2 diabetes
1 199
1 199
Gleevec/Glivec
Established Brands
Chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GIST)
315
873
1 188
Afinitor/Votubia
Established Brands
Breast cancer/ tuberous sclerosis complex (TSC)
644
439
1 083
Diovan Group
Established Brands
Hypertension
124
879
1 003
Exforge Group
Established Brands
Hypertension
16
964
980
Zolgensma
Neuroscience
Spinal muscular atrophy (SMA)
459
461
920
Ilaris
Immunology
Auto-inflammatory (CAPS, TRAPS, HIDS/MKD, FMF, SJIA, AOSD gout)
400
473
873
Kisqali
Solid Tumors
HR+/HER2- metastatic breast cancer
318
369
687
Exjade/Jadenu
Established Brands
Chronic iron overload
138
515
653
Votrient
Solid Tumors
Renal cell carcinoma (RCC)
259
376
635
Top 20 products total
11 126
18 790
29 916
Rest of portfolio
3 216
5 881
9 097
Total division net sales to third parties
14 342
24 671
39 013
 1  Brand classifications have been changed to reflect the new Innovative Medicines divisional structures announced on April 4, 2022.
 2  Net sales to third parties reflect Xolair sales for all indications.
Sandoz [member]  
Statement [line items]  
Net sales
Sandoz Division net sales to third parties by business franchise


2022
USD m


2021
USD m
Change
(2021 to
2022)
USD %


2020
USD m
Change
(2020 to
2021)
USD %
Retail Generics 1
6 776
7 092
-4
7 244
-2
Biopharmaceuticals
2 093
2 116
-1
1 928
10
Anti-Infectives 1
380
423
-10
474
-11
Total division net sales to third parties
9 249
9 631
-4
9 646
0
 1  Sandoz total anti-infectives net sales to third parties amounted to USD 1.2 billion (2021: USD 1.1 billion; 2020: USD 1.2 billion), of which USD 777 million (2021: USD 707 million; 2020: USD 694 million) is sold through the Retail Generics business franchise and USD 380 million (2021: USD 423 million; 2020: USD 474 million) is sold to other third-party companies through the Anti-Infectives business franchise.